Patents by Inventor Mark Matteucci

Mark Matteucci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10829437
    Abstract: Provided herein are compounds of formula I, wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: November 10, 2020
    Assignee: OBI PHARMA, INC.
    Inventors: Jian-Xin Duan, Yeyu Cao, Xiaohong Cai, Hailong Jiao, Jing Yuan Ma, Mark Matteucci
  • Patent number: 10766914
    Abstract: Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: September 8, 2020
    Assignee: OBI PHARMA, INC.
    Inventors: Jian-Xin Duan, Yeyu Cao, Xiaohong Cai, Hailong Jiao, Jing Yuan Ma, Mark Matteucci
  • Patent number: 10668047
    Abstract: Provided herein are compounds of formula (I)-(VI): wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: June 2, 2020
    Assignee: Molecular Templates, Inc.
    Inventors: Mark Matteucci, Xiaohong Cai, Yeyu Cao, Hailong Jiao, Jing Yuan Ma, Jian-Xin Duan
  • Patent number: 10654876
    Abstract: The present invention provides a new method for making TH-302 and solid forms thereof. The compound in its solid form is an effective anti-cancer agent and may be used in various pharmaceutical compositions, and are particularly effective for the treatment of cancer. The invention also provides a method for preparing such compounds and forms and for treating cancer in a mammal comprising the step of administering a therapeutically effective amount of a solid form of TH-302 thereof.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: May 19, 2020
    Assignee: Molecular Templates, Inc.
    Inventors: Jian-Xin Duan, Mark Matteucci, Nipun Davar, Denise Andersen
  • Publication number: 20200085786
    Abstract: Provided herein are compounds of formula (I)-(VI): wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.
    Type: Application
    Filed: April 23, 2019
    Publication date: March 19, 2020
    Inventors: Mark Matteucci, Xiaohong Cai, Yeyu Cao, Hailong Jiao, Jing Yuan Ma, Jian-Xin Duan
  • Patent number: 10409869
    Abstract: Provided herein are optically active compounds of the formulae (ii); and (III) and pharmaceutical compositions thereof. Also provided herein are processes of making these compounds and resolving the racemic mixture or the enrichment of same with in one of its enantiomers to provide (R)- and (S)-1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-N,N?-bis(ethylene)phosphoramidate, and methods of treating cancer comprising administering such compounds.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: September 10, 2019
    Assignee: OBI PHARMA, INC.
    Inventors: Jian-Xin Duan, Yeyu Cao, Xiaohong Cai, Hailong Jiao, Jing Yuan Ma, Mark Matteucci
  • Patent number: 10364261
    Abstract: Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: July 30, 2019
    Assignee: OBI PHARMA, INC.
    Inventors: Jian-Xin Duan, Yeyu Cao, Xiaohong Cai, Hailong Jiao, Jing Yuan Ma, Mark Matteucci
  • Publication number: 20190225633
    Abstract: Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.
    Type: Application
    Filed: March 28, 2019
    Publication date: July 25, 2019
    Applicant: OBI PHARMA, INC.
    Inventors: Jian-Xin Duan, Yeyu Cao, Xiaohong Cai, Hailong Jiao, Jing Yuan Ma, Mark Matteucci
  • Publication number: 20190127404
    Abstract: The present invention provides a new method for making TH-302 and solid forms thereof. The compound in its solid form is an effective anti-cancer agent and may be used in various pharmaceutical compositions, and are particularly effective for the treatment of cancer. The invention also provides a method for preparing such compounds and forms and for treating cancer in a mammal comprising the step of administering a therapeutically effective amount of a solid form of TH-302 thereof.
    Type: Application
    Filed: November 16, 2018
    Publication date: May 2, 2019
    Applicant: Molecular Templates, Inc.
    Inventors: Jian-Xin Duan, Mark Matteucci, Nipun Davar, Denise Andersen
  • Patent number: 10131683
    Abstract: The present invention provides a new method for making TH-302 and solid forms thereof. The compound in its solid form is an effective anti-cancer agent and may be used in various pharmaceutical compositions, and are particularly effective for the treatment of cancer. The invention also provides a method for preparing such compounds and forms and for treating cancer in a mammal comprising the step of administering a therapeutically effective amount of a solid form of TH-302 thereof.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: November 20, 2018
    Assignee: Molecular Templates, Inc.
    Inventors: Jian-Xin Duan, Mark Matteucci, Nipun Davar, Denise Andersen
  • Publication number: 20180258116
    Abstract: Provided herein are optically active compounds of the formulae (ii); and (III) and pharmaceutical compositions thereof. Also provided herein are processes of making these compounds and resolving the racemic mixture or the enrichment of same with in one of its enantiomers to provide (R)- and (S)-1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-N,N?-bis(ethylene)phosphoramidate, and methods of treating cancer comprising administering such compounds.
    Type: Application
    Filed: November 15, 2016
    Publication date: September 13, 2018
    Applicant: OBI Pharma, Inc.
    Inventors: Jian-Xin Duan, Yeyu Cao, Xiaohong Cai, Hailong Jiao, Jing Yuan Ma, Mark Matteucci
  • Publication number: 20180169064
    Abstract: Provided herein are compounds of formula (I)-(VI), wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.
    Type: Application
    Filed: June 23, 2016
    Publication date: June 21, 2018
    Inventors: Mark Matteucci, Xiaohong Cai, Yeyu Cao, Hailong Jiao, Jing Yuan Ma, Jian-Xin Duan
  • Publication number: 20180086693
    Abstract: Provided herein are compounds of formula I, wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.
    Type: Application
    Filed: April 1, 2016
    Publication date: March 29, 2018
    Applicant: OBI PHARMA, INC.
    Inventors: Jian-Xin Duan, Yeyu Cao, Xiaohong Cai, Hailong Jiao, Jing Yuan Ma, Mark Matteucci
  • Publication number: 20180044360
    Abstract: Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.
    Type: Application
    Filed: March 9, 2016
    Publication date: February 15, 2018
    Applicant: OBI PHARMA, INC.
    Inventors: Jian-Xin Duan, Yeyu Cao, Xiaohong Cai, Hailong Jiao, Jing Yuan Ma, Mark Matteucci
  • Publication number: 20170210769
    Abstract: The present invention provides a new method for making TH-302 and solid forms thereof. The compound in its solid form is an effective anti-cancer agent and may be used in various pharmaceutical compositions, and are particularly effective for the treatment of cancer. The invention also provides a method for preparing such compounds and forms and for treating cancer in a mammal comprising the step of administering a therapeutically effective amount of a solid form of TH-302 thereof.
    Type: Application
    Filed: July 15, 2015
    Publication date: July 27, 2017
    Applicant: THRESHOLD PHARMACEUTICALS, INC.
    Inventors: Jian-Xin Duan, Mark Matteucci, Nipun Davar, Denise Andersen
  • Patent number: 9226932
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: January 5, 2016
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao
  • Publication number: 20150258125
    Abstract: Cancer can be treated by administration of a hypoxia-activated prodrug, such as TH-302, alone or in combination with other anticancer agents and/or radiation therapy. In combination therapy, the hypoxia-activated prodrug and another anticancer agent or radiation therapy may be administered within the same 24-hour period, and administration of the hypoxia-activated prodrug may be completed prior to beginning administration of the other anticancer agent or radiation therapy.
    Type: Application
    Filed: December 17, 2014
    Publication date: September 17, 2015
    Inventors: John G. Curd, Stewart Kroll, Mark Matteucci, Charles P. Hart, Jian-Xin Duan, Jessica D. Sun
  • Patent number: 8946275
    Abstract: Cancer can be treated by administration of a hypoxia-activated prodrug, such as TH-302, alone or in combination with other anticancer agents and/or radiation therapy. In combination therapy, the hypoxia-activated prodrug and another anti-cancer agent or radiation therapy may be administered within the same 24-hour period, and administration of the hypoxia-activated prodrug may be completed prior to beginning administration of the other anticancer agent or radiation therapy.
    Type: Grant
    Filed: October 21, 2009
    Date of Patent: February 3, 2015
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Stewart Kroll, Mark Matteucci, Charles P. Hart, Jian-Xin Duan, Karen Curd
  • Publication number: 20140170240
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Application
    Filed: December 10, 2013
    Publication date: June 19, 2014
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao
  • Publication number: 20140072624
    Abstract: Formulations and unit dose forms of TH-302 and other hypoxia activated prodrugs suitable for oral administration are useful for treating cancer.
    Type: Application
    Filed: April 13, 2012
    Publication date: March 13, 2014
    Applicant: THRESHOLD PHARMACEUTICALS, INC.
    Inventors: Donald Jung, Mark Matteucci, Stewart Kroll